Medical technology developer Medtronic, Inc. recently completed an application submission to the U.S. Food and Drug Administration (FDA) regarding the pre-market approval of their SynchroMed II implantable drug infusion system, which includes a new catheter design. The system is intended to be used by pulmonary arterial hypertension (PAH) patients for the intravenous delivery of the drug Remodulin (treprostinil), which is being developed by the United Therapeutics Corporation.
{iframe}http://lungdiseasenews.com/2014/12/29/medtronic-submits-drug-delivery-system-to-fda-to-complement-united-therapeutics-pah-treatment/{/iframe}